💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Nizatidine

CHEMBL3183075 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
331.5 g/mol
LogP
1.6
Phase
4

Histamine H2 receptors on gastric parietal cells drive acid secretion, and nizatidine blocks them. Reducing acid output allows peptic ulceration to heal and relieves the symptoms of gastro-oesophageal reflux, particularly heartburn. The H2 antagonist class occupies an intermediate position between antacids, which neutralise acid already secreted, and proton pump inhibitors, which act on the terminal step of secretion; H2 blockade suppresses the histamine-driven component specifically. The compound is a small molecule with the formula C12H21N5O2S2 and a molecular weight of roughly 331.5 g/mol. It is an approved agent that has completed the final phase of clinical development, and remains a recognised member of its therapeutic class.

An H2 blocker that reduces stomach acid production to help heal ulcers and relieve heartburn.

Molekularmasse

331,5000 g/mol

LogP

1,60

TPSA

140,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Gastroesophageal Reflux Disease Gastroenterology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C12H21N5O2S2

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
Rotierbare Bindungen

                        
9

                    

                    
                    
                    

                        
Schwere Atome

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
An H2 blocker that reduces stomach acid production to help heal ulcers and relieve heartburn.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Nizatidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3183075.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4513.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.